Plasmacytoid urothelial carcinoma is rare and aggressive, with poor outcomes and challenges in accurate staging. National and institutional data reveal discrepancies in chemotherapy use and disease ...

Objective: To investigate the optimal cut-off value of immunohistochemical marker Ki67 as a prognostic factor to predict the recurrence of non-muscle invasive bladder urothelial carcinoma (NMIBUC).

In this video, Fed Ghali, MD, highlights key findings from the study, “Evaluating Clinical Outcomes and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a ...

Drug-induced hyponatremia is an adverse reaction with accelerated electrolyte disturbance. This study reported a rare case of delayed hyponatremia in a 68year-old female with recurrent upper tract ...

Five percent of newly diagnosed patients have metastatic disease. Metastatic urothelial carcinoma (mUC) is primarily treated with cisplatin-based chemotherapy, immunotherapy, targeted therapy, or ...

Skin cancer is by far the most common type of cancer in the United States. Merkel cell carcinoma (MCC) is a type of skin cancer, but it's not common. About 3,000 people are diagnosed with Merkel cell ...

Our study provides insight into the treatment landscape and outcomes for metastatic urothelial carcinoma in Mexico and highlights the need for improved access to novel therapies. These findings can ...

The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or metastatic urothelial cancer and nivolumab plus cisplatin and gemcitabine ...

Patients with muscle-invasive urothelial cancer face a high risk of relapse despite radical surgery and chemotherapy. The immune checkpoint inhibitor pembrolizumab may reduce this risk.

What is a 5-year relative survival rate? Where do these numbers for Merkel cell carcinoma come from? 5-year relative survival rates for Merkel cell carcinoma Understanding the numbers Keep in mind ...

The various types of exocrine pancreatic cancers make up more than 95 percent of all cancers of the pancreas. They include the following: Also called ductal carcinoma, adenocarcinoma, is the most ...